GERN
GERON CORP
NASDAQ · Healthcare · Biotechnology · US
$1.30
−1.52%Sep 18, 2026, 20:01 UTC
Geron Corporation granted stock options to purchase an aggregate of 821,250 shares of common stock to nine newly hired employees as an inducement to their acceptance of employment, effective September 17, 2026.
Source:Sep 14, 2026, 18:16 UTC
Kahn Swick & Foti, LLC commenced an investigation into the officers and directors of Geron Corporation.
Source:Aug 5, 2026, 11:00 UTC
Geron Corporation reported second quarter 2026 financial results, with RYTELO net product revenue of $57.5 million, an 11% increase from the first quarter of 2026, and cash and marketable securities of $327 million at the end of the quarter.
Jul 13, 2026, 12:00 UTC
Geron Corporation appointed Chinmaya Rath as Chief Business Officer.
Jul 1, 2026, 14:11 UTC
Geron Corporation reported Q1'26 Rytelo revenues of $51.8 million, up 8% sequentially, with two consecutive quarters of demand growth.
Source:Jun 1, 2026, 20:05 UTC
Fulcrum Therapeutics discontinued its pociredir program in sickle cell disease following FDA feedback about secondary malignancies observed with Tazverik and its global withdrawal.
Jun 1, 2026, 18:06 UTC
Replimune aligned with the FDA on plans to resubmit its Biologics License Application for RP1 plus Opdivo in advanced melanoma.
Source:Jun 1, 2026, 18:00 UTC
Merck's calderasib plus Keytruda received FDA Breakthrough Therapy designation for newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
Source:Jun 1, 2026, 16:32 UTC
Iovance Biotherapeutics obtained FDA clearance of an Investigational New Drug application for IOV-5001, extending its cell therapy platform into solid tumors.
Source:Jun 1, 2026, 12:30 UTC
PolyPid completed a New Drug Application submission to the FDA for D-PLEX100.
Source:Jun 1, 2026, 11:00 UTC
Kamada Ltd. received FDA approval for its new in-house Rabies Virus Neutralization Testing Laboratory.
Source:Jun 1, 2026, 09:53 UTC
Geron received FDA approval for RYTELO in low- to intermediate-1 risk MDS.
Source: